

Docket No.: 1459-011



TRANSMITTAL OF CERTIFIED PRIORITY DOCUMENT(S)

PATENT

TECH CENTER 1600/2900

MAR 21 2002

RECEIVED

# 27

Linda  
3/26/02

In re Application of

Yoke Min SIN, et al.

Serial No. 09/196,161

Filed: November 20, 1998

:  
:  
:  
:  
:  
:  
:

Group Art Unit: 1642

Examiner: Nita M. Minnifield

For: RECOMBINANT VACCINE AGAINST INFECTIONS DISEASE IN FISH

Commissioner for Patents  
Washington, D.C. 20231

Sir:

At the time the above application was filed, priority was claimed based on the following applications(s):

9803188-3

Singapore

28 September 1998

A copy of each priority application listed above is enclosed.

LOWE HAUPTMAN GILMAN & BERNER, LLP

Michael G. Gilman  
Registration No. 19,114

1700 Diagonal Road, Suite 310  
Alexandria, Virginia 22314  
(703) 684-1111  
(703) 518-5499 Facsimile  
MGG/vgg



**REGISTRY OF PATENTS  
SINGAPORE**

This is to certify that the annexed is a true copy of the following  
Singapore patent application as filed in this Registry.

Date of Filing : 28 SEPTEMBER 1998

Application Number : 9803188-3

Applicant(s) : NATIONAL UNIVERSITY OF SINGAPORE

Title of Invention : A RECOMBINANT VACCINE AGAINST  
INFECTIOUS DISEASE IN FISH

TECH CENTER 1600/2900

MAR 21 2002

RECEIVED

Sharmaine Wu Shee Mei  
Assistant Registrar  
for REGISTRAR OF PATENTS  
SINGAPORE

**SECOND SCHEDULE  
SINGAPORE  
THE PATENTS ACT  
(CHAPTER 221)**

*The Registrar of Patents  
Registry of Patents*

**THE PATENTS RULES**

**REQUEST FOR THE GRANT OF A PATENT**

**THE GRANT OF A PATENT IS REQUESTED BY THE UNDERSIGNED ON THE BASIS OF  
THE PRESENT APPLICATION.**

<b>I. Title of Invention</b>	A Recombinant Vaccine Against Infectious Disease In Fish		
<b>II. Applicant(s)</b> (See note 2)	(a) Name	National University of Singapore	
	Body Description/ Residency	Incorporated in Singapore	
	Street Name & Number	Industry & Technology Relations Office National University of Singapore 10 Kent Ridge Crescent	
	City	Singapore 119260	
	State	Singapore	
	Country	Singapore	
	(b) Name		
	Body Description/ Residency		
	Street Name & Number		
	City		
	State		
	Country		
	(c) Name		
	Body Description/ Residency		
	Street Name & Number		
	City		
	State		
	Country		
<b>III. Declaration of priority</b> (See note 3)	Country/Country Designated		File no.
	Filing Date		
	Country/Country Designated		File no.
	Filing Date		
	Country/Country Designated		File no.
	Filing Date		

**RECEIVED**  
MAR 21 2002  
TECH CENTER 100/2900

**SECOND SCHEDULE - continued**

<b>IV. Inventors</b> (See note 4) (a) The applicant(s) is/are the sole/joint inventor(s). (b) A statement on Patents Form 8 is/will be furnished.	<table style="margin: auto;"> <tr> <td><input type="checkbox"/></td> <td>Yes</td> <td><input checked="" type="checkbox"/></td> <td>No</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Yes</td> <td><input type="checkbox"/></td> <td>No</td> </tr> </table>	<input type="checkbox"/>	Yes	<input checked="" type="checkbox"/>	No	<input checked="" type="checkbox"/>	Yes	<input type="checkbox"/>	No										
<input type="checkbox"/>	Yes	<input checked="" type="checkbox"/>	No																
<input checked="" type="checkbox"/>	Yes	<input type="checkbox"/>	No																
<b>V. Name of Agent (if any)</b> (See note 5)	Applied Research Corporation																		
<b>VI. Address for Service</b> (See note 6)	<table style="width:100%;"> <tr> <td style="width:25%;">Block/Hse No</td> <td style="width:25%;"></td> <td style="width:25%;">Level No</td> <td style="width:25%;"></td> </tr> <tr> <td>Unit No/PO Box</td> <td>Kent Ridge P.O.BOX 1016</td> <td>Postal Code</td> <td>911101</td> </tr> <tr> <td>Street Name</td> <td colspan="3"></td> </tr> <tr> <td>Building Name</td> <td colspan="3"></td> </tr> </table>	Block/Hse No		Level No		Unit No/PO Box	Kent Ridge P.O.BOX 1016	Postal Code	911101	Street Name				Building Name					
	Block/Hse No		Level No																
	Unit No/PO Box	Kent Ridge P.O.BOX 1016	Postal Code	911101															
	Street Name																		
Building Name																			
<b>VII. Claiming an earlier filing date under section 20(3), 26(6) or 47(4).</b> (See note 7)	<table style="width:100%;"> <tr> <td style="width:40%;">Application No</td> <td colspan="3"></td> </tr> <tr> <td>Filing Date</td> <td></td> <td></td> <td></td> </tr> </table>	Application No				Filing Date													
	Application No																		
Filing Date																			
<b>VIII. Invention has been displayed at an International Exhibition</b> (See note 8)	<table style="margin: auto;"> <tr> <td><input type="checkbox"/></td> <td>Yes</td> <td><input checked="" type="checkbox"/></td> <td>No</td> </tr> </table>	<input type="checkbox"/>	Yes	<input checked="" type="checkbox"/>	No														
<input type="checkbox"/>	Yes	<input checked="" type="checkbox"/>	No																
<b>XI. Section 114 requirement</b> (See note 9)	The invention relates to and/or uses a micro-organism deposited for the purposes of disclosure in accordance with section 114 with a depositary authority under the Budapest Treaty.  <div style="text-align: center;"> <input type="checkbox"/> Yes      <input checked="" type="checkbox"/> No         </div>																		
<b>X. Check List</b> (To be filled in by applicant or agent)	<b>A. The application contains the following number of sheet(s):-</b> <table style="width:100%;"> <tr> <td style="width:70%;">1. Request.</td> <td style="width:10%; text-align: center;">3</td> <td style="width:20%;">sheets</td> </tr> <tr> <td>2. Description.</td> <td style="text-align: center;">15</td> <td>sheets</td> </tr> <tr> <td>3. Claim(s).</td> <td style="text-align: center;">3</td> <td>sheets</td> </tr> <tr> <td>4. Drawing(s).</td> <td style="text-align: center;">3</td> <td>sheets</td> </tr> <tr> <td>5. Abstract.</td> <td style="text-align: center;">1</td> <td>sheets</td> </tr> </table>	1. Request.	3	sheets	2. Description.	15	sheets	3. Claim(s).	3	sheets	4. Drawing(s).	3	sheets	5. Abstract.	1	sheets			
	1. Request.	3	sheets																
	2. Description.	15	sheets																
	3. Claim(s).	3	sheets																
4. Drawing(s).	3	sheets																	
5. Abstract.	1	sheets																	
<b>B. The application as filed is accompanied by:-</b> <table style="width:100%;"> <tr> <td style="width:70%;">1. Priority document.</td> <td style="width:10%; text-align: center;"><input type="checkbox"/></td> <td style="width:20%;"></td> </tr> <tr> <td>2. Translation of priority document.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td></td> </tr> <tr> <td>3. Statement of Inventorship &amp; right to grant.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td></td> </tr> <tr> <td>4. International Exhibition Certificate..</td> <td style="text-align: center;"><input type="checkbox"/></td> <td></td> </tr> </table>	1. Priority document.	<input type="checkbox"/>		2. Translation of priority document.	<input type="checkbox"/>		3. Statement of Inventorship & right to grant.	<input checked="" type="checkbox"/>		4. International Exhibition Certificate..	<input type="checkbox"/>								
1. Priority document.	<input type="checkbox"/>																		
2. Translation of priority document.	<input type="checkbox"/>																		
3. Statement of Inventorship & right to grant.	<input checked="" type="checkbox"/>																		
4. International Exhibition Certificate..	<input type="checkbox"/>																		
<b>XI. Signature(s)</b> (See note 10)	<table style="width:100%;"> <tr> <td style="width:30%;">Applicant (a)</td> <td colspan="2"></td> </tr> <tr> <td>Date</td> <td>28-9-98</td> <td></td> </tr> <tr> <td>Applicant (b)</td> <td colspan="2"></td> </tr> <tr> <td>Date</td> <td></td> <td></td> </tr> <tr> <td>Applicant (c)</td> <td colspan="2"></td> </tr> <tr> <td>Date</td> <td></td> <td></td> </tr> </table>	Applicant (a)			Date	28-9-98		Applicant (b)			Date			Applicant (c)			Date		
	Applicant (a)																		
	Date	28-9-98																	
	Applicant (b)																		
	Date																		
	Applicant (c)																		
Date																			

SECOND SCHEDULE — *continued*

## NOTES:

1. This form when completed, should be brought or sent to the Registry of Patents together with the prescribed fee and 3 copies of the description of the invention, and of any drawings.
2. Enter the name and address of each applicant in the spaces provided at paragraph II. Names of individuals should be indicated in full and the surname or family name should be underlined. The names of all partners in a firm must be given in full. The place of residence of each individual should also be furnished in the space provided. Bodies corporate should be designated by their corporate name and country of incorporation and, where appropriate, the state of incorporation within that country should be entered where provided. Where more than three applicants are to be named, the names and address of the fourth and any further applicants should be given on a separate sheet attached to this Form together with the signature of each of these further applicants.
3. The declaration of priority at paragraph III should state the date of the previous filing, the country in which it was made, and indicate the file number, if available. Where the application relied upon in an International Application or a regional patent application e.g. European patent application, one of the countries designated in that application (being one falling under the Patents (Convention Countries) Order) should be identified and the name of that country should be entered in the space provided.
4. Where the applicant or applicants is/are the sole inventor or the joint inventors, paragraph IV should be completed by marking the 'YES' Box in the declaration (a) and the 'NO' Box in the alternative statement (b). Where this is not the case, the 'NO' Box in declaration (a) should be marked and a statement will be required to be filed on Patents Form 8.
5. If the applicant has appointed an agent to act on his behalf, the agent's name should be indicated in the spaces available at paragraph V.
6. An address for service in Singapore to which all documents may be sent must be stated at paragraph VI. It is recommended that a telephone number be provided if an agent is not appointed.
7. When an application is made by virtue of section 20(3), 26(6) or 47(4), the appropriate section should be identified at paragraph VII and the number of the earlier application or any patent granted thereon identified.
8. Where the applicant wishes an earlier disclosure of the invention by him at an International Exhibition to be disregarded in accordance with section 14(4)(c), then the 'YES' box at paragraph VIII should be marked. Otherwise the 'NO' box should be marked.
9. Where in disclosing the invention the application refers to one or more micro-organisms deposited with a depository authority under the Budapest Treaty, then the 'YES' box at paragraph IX should be marked. Otherwise the 'NO' box should be marked.
10. Attention is drawn to rules 90 and 105 of the Patent Rules. Where there are more than three applicants, see also Note 2 above.
11. Applicants resident in Singapore are reminded that if the Registry of Patents considers that an application contains information the publication of which might be prejudicial to the defence of Singapore or the safety of the public, it may prohibit or restrict its publication or communication. Any person resident in Singapore and wishing to apply for patent protection in other countries must first obtain permission from the Singapore Registry of Patents unless they have already applied for a patent for the same invention in Singapore. In the latter case, no application should be made overseas until at least two months after the application has been filed in Singapore.

## For Official Use

Application Filing Date:        /        /

Request received on        :        /        /

Fee received on        :        /        /

Amount        :

\*Cash/Cheque/Money Order No:

\*Delete whichever is inapplicable

## A RECOMBINANT VACCINE AGAINST INFECTIOUS DISEASE IN FISH

### TECHNICAL FIELD

This invention is directed to a recombinant vaccine for immunizing fish against white spot disease (also known as ich ).

### BACKGROUND OF THE INVENTION

White spot disease is a severe infectious disease that adversely affects warm water fish. It is caused by a ciliated ectoparasitic protozoan, *Ichthyophthirius multifiliis* that causes high morbidity and mortality in many freshwater fish. In the past, when fish show clinical signs of infection by this disease, they have commonly been treated with chemicals (Cross, D.G., "A REVIEW OF METHODS TO CONTROL ICHTHYOPHTHIRIASIS", Prog. Fish-culture, 34, (1972) 165-169; Gratzek, J.B., "CONTROL AND THERAPY OF FISH DISEASES", Advances Vet. Sci. Comparat. Med., 27, (1983) 297-324; Post, G., "TEXTBOOK OF FISH HEALTH" (Revised and expanded edition), T.F.H. Publications Inc, USA, 1987). However, these chemicals usually leave residues in the fish tissues that can endanger not only the health of the fish, but they can also adversely affect humans who are the ultimate consumers of the infected fish.

On the other hand, protection of many fish species against Ichthyophthiriasis has been reported through the use of immunization with *I. Multifiliis*. Such reports of immunized fish include:

goldfish (Ling, K.H., Sin, Y.M. and Lam, T.J., "PROTECTION OF GOLDFISH AGAINST SOME COMMON ECTOPARASITIC PROTOZOANS USING *ICHTHYOPHTHIRIUS MULTIFILIIS* AND *TETRAHYMENA PYRIFORMIS* FOR VACCINE", Aquaculture, 116 ( 1993) 303-314;

mirror carp (Hines, R.S. and Spira, D.T., "ICHTHYOPHTHIRIASIS IN THE MIRROR CARP *CYPRINUS CARPIO* (L), IV. PHYSIOLOGICAL DISFUNCTION", J. Fish Biol., 6 (1974) 365-371;

channel catfish (Gover, B.A., Dawe, D.L. and Gratzek, B., "PROTECTION OF CHANNEL CATFISH, *ICTALURUS PUNCTATUS* RAFINESQUE, AGAINST *I. MULTIFILIIS* FOUQUET BY IMMUNIZATION", J.Fish Biol., 17 (1980) 311-316 ;

rainbow trout (Wolf, K. and Markiw, M.E., "ICHTHYOPHTHIRIASIS: IMMERSION IMMUNIZATION OF RAINBOW TROUT (*SALMO GAIIRDNERI* ) USING *TETRAHYMENA THERMOPHILA* AS A PROTECTIVE IMMUNOGEN", Can. J. Fish Aquat. Sci., 39 (1982) 1772-1725;

tilapia (Subasinghe, R.P. and Sommerville, C., "ACQUIRED IMMUNITY OF *OREOCHROMIS MOSSAMBISCUS* TO THE CILIATE ECTOPARASITE *ICHTHYOPHTHIRIUS MULTIFILIIS* (FOUQUET)" In : J.L Maclean, L.B. Dizon and L.V. Osillos (editors), The first Asian Fisheries Forum, Asean Fisheries Society, Manila, Philippines, 1987, 279-283); and

some other common ornamental fish (Ling K.H., Sin Y.M. and Lam T.J., "A NEW APPROACH TO CONTROLLING ICHTHYOPHTHIRIASIS IN A CLOSED CULTURE SYSTEM OF FRESHWATER ORNAMENTAL FISH", J. fish Dis., 14 (1991) 595-598).

Until now, no known methods have been reported as to how to *in vitro* grow the protozoan, *I. Multifiliis*, that has caused the problem. The vaccines (whole cells, cell fragments or extracts of the pathogen), that have been prepared and used by different laboratories, have only been obtained from an infected live fish since the offending protozoan is an obligate parasite. Preparation of such vaccines from live fish is very time-consuming, costly and impractical.

An antigenic relationship has been demonstrated between *I. Multifiliis* and *Tetrahymena pyriformis* , a free-living and cultivable non-pathogenic ciliated protozoan (Goven , B.A., Dawe, D.L. and Gratzek, J.B., "PROTECTION OF CHANNEL CATFISH, *ICTALURUS PUNCTATUS* RAFINESQUE, AGAINST *ICHTHYOPHTHIRIUS MULTIFILIIS* FOUQUET BY IMMUNIZATION", J. Fish Biol., 17 (1980) 311-316). These workers suggested that *T. pyriformis* could be used as a vaccine for inducing protection against Ichthyophthiriasis (Goven,B.A., Dawe, D.L and Gratzek, J.B., " *IN VITRO* DEMONSTRATION OF SEROLOGICAL CROSS-REACTIVITY BETWEEN *ICHTHYOPHTHIRIUS MULTIFILIIS* FOUQUET AND *T. PYRIFORMIS* LWOFF", Dev.

Comp. Immunol., 5 (1981) 283-289). A ciliary protein extracted from *T. pyriformis* was shown to be an effective vaccine against the disease caused by *I. Multifiliis* in freshwater fish and *Cryptocaryon* in marine fish (U.S. Patent Number 4,309,416). The presence of an immobilization antigen (i-Ag) in *I. Multifiliis* was reported by Dickerson, H.W., Clark, T.G. and Findly, R.C., "*ICHTHYOPHTHIRIUS MULTIFILIIS* : HAS MEMBRANE-ASSOCIATED IMMOBILIZATION ANTIGENS", J. Protozool., 36 (1989) 159-164 ) and by Lin, T.L. and Dickerson, H.W., "PURIFICATION AND PARTIAL CHARACTERIZATION OF IMMOBILIZATION ANTIGEN FROM *ICHTHYOPHTHIRIUS MULTIFILIIS*", J. Protozool., 39 (1992) 457-463).

A partial cDNA clone for 48 kDa i-Ag was isolated from a cDNA library and the amino acid sequence that was deduced from the cDNA clone contained three tandem repeats (Clark, T.G., McGraw, R.A. and Dickerson, H.W., "DEVELOPMENTAL EXPRESSION OF SURFACE ANTIGEN GENES IN THE PARASITIC CILIATE *ICHTHYOPHTHIRIUS MULTIFILIIS*", Proc. Natl. Acad. Sci. USA, 89 (1992) 6363-6367). In fact, the degree of immune protection was correlated with the levels of antibody titers against this immobilization antigen in the plasma and skin mucus of the fish that had been immunized against *I. Multifiliis* (Clark, T.G., Dickerson, H.W., and Findly, R.C., "IMMUNE RESPONSE OF CHANNEL CATFISH TO CILIARY ANTIGENS OF *ICHTHYOPHTHIRIUS MULTIFILIIS*", Devel. Comp. Immunol., 12 (1988) 581-594 and *T. pyriformis* ( Ling, K.H., Sin, Y.M. and Lam T.J., "PROTECTION OF GOLDFISH AGAINST SOME COMMON ECTOPARASITIC PROTOZOANS USING *ICHTHYOPHTHIRIUS MULTIFILIIS* AND *TETRAHYMENA PYRIFORMIS* FOR VACCINATION", Aquaculture, 116 (1993) 303-314). Fish immunized with *I. Multifiliis* and *T. pyriformis* by immersion and intraperitoneal injection developed protective immunity not only against *I. Multifiliis*, but also against other ciliated ectoparasitic protozoans that are commonly found in the tropics (Ling, K.H., Sin, Y.M. and Lam T.J., "PROTECTION OF GOLDFISH AGAINST SOME COMMON ECTOPARASITIC PROTOZOANS USING *ICHTHYOPHTHIRIUS MULTIFILIIS* AND *TETRAHYMENA PYRIFORMIS* FOR VACCINATION", Aquaculture, 116 (1993) 303-314).



Since the chemicals that have been found to be effective against these adverse ciliated protozoans are not approved for use in food fish by the USDA, and many other countries in the world, immunization may be the only practical approach to controlling this white spot disease. This can be done by either direct immunization of the fish with vaccines, using whole cells or ciliary protein extracts from *I. multifiliis*, as discussed above or by passive protection using immobilization antibodies against the pathogen released by the immunized fish in a closed culture system (U.S. Patent Number 5,643,571).

## OBJECTS AND BRIEF DESCRIPTION OF THE INVENTION

An important object of this invention is to provide an effective vaccine for immunization against infectious fish ectoparasitic protozoan, *Ichthyophthirius multifiliis* (He, J., Yin, Z., Xu, G., Gong, Z., Lam, T.J. and Sin, Y.M., "PROTECTION OF GOLDFISH AGAINST *ICHTHYOPHTHIRIUS MULTIFILIIS* BY IMMUNIZATION WITH A RECOMBINANT VACCINE", Aquaculture, 158(1997)1-10) that has been produced by recombinant techniques, since no vaccine has as yet been obtained, nor is it likely that one can be obtained, using *in vitro* systems.

Another object of this invention is to provide an effective vaccine for the immunization of fish, not only against *Ichthyophthirius multifiliis*, but also against other, taxonomically related, ciliated ectoparasitic protozoans, by recombinant techniques.

A further object of this invention is to provide a feasible method for commercial production of this vaccine.

Other and additional objects will become apparent from a consideration of this entire specification including the claims appended hereto.

In accordance with and fulfilling these objects, one aspect of this invention is a vaccine against ciliated protozoan infection that has been prepared by recombinant techniques. A gene fragment, containing a complete repeat I of *I. Multifiliis*, was synthesized and assembled based on the amino acid sequence of i-Agl. The recombinant i-

AgI was expressed in bacteria, as a glutathione S-transferase (GST-iAgI) fusion protein. The fusion protein was purified from bacterial lysate and successfully used as a vaccine for immunization. The modified sequences according to this invention can be used to produce the recombinant fusion protein by any organism. These are exemplified by: yeast, baculovirus in insect cells, transgenic mammals, other vertebrate and invertebrate and transgenic plants using universal genetic codons. These universal codons are CAG and CAA, which are glutamine codons.

### **BRIEF DESCRIPTION OF THE DRAWING**

Fig 1A is an illustration of the epitope of i-Ag included in a GST-iAgI recombinant protein;

Fig. 1B is an illustration of six synthetic oligonucleotides that were used to construct the i-AgI epitope region;

Fig. 1C is a diagram of the plasmid pGST-iAgI that was used for the production of GST-iAgI protein;

Figs. 2(A) is a plan view of a gel electrophoresis of bacterial expressions of GST-iAgI fusion protein; and

Fig 2(B) is a plan view of a Western Blot analysis.

### **DETAILED DESCRIPTION OF THE INVENTION**

A 316 bp gene fragment containing an antigenic epitope of the 48K immobilization antigen of *Ichthyophthirius multifiliis* (iAgI) was assembled from six synthetic oligonucleotides and cloned into a bacterial expression vector pGEX2T. The gene construct was introduced into *Escherichia coli* and the glutathione S-transferase-iAgI (GST-iAgI) fusion protein was successfully expressed. Antisera against GST-iAgI fusion protein from catfish showed a positive reaction with a tomite protein of about 48K,

suggesting that the recombinant protein contains an antigenic epitope of i-AgI. Naive goldfish, that were immunized with purified GST-iAgI fusion protein, were challenged with a lethal dose of infectious tomites of *I. Multifiliis*. The results showed that the recombinant GST-iAgI fusion protein can be used as a vaccine against the infection of not only *I. Multifiliis* but also against diseases caused by other taxonomically similar pathogens, that is the ciliated ectoparasitic protozoans.

Referring now to Fig. 1(A), the amino acid sequence of the epitope of i-Ag is set forth on line I, the corresponding nucleotide sequences from the original i-Ag cDNA clone are set forth on line II, and the synthetic DNA fragment of this invention is set forth on line III.. This Fig. aligns these three sequences. Two conserved amino acid substitutions between the original and the synthetic i-AgI DNAs have been indicated as A/S and V/G, where S and G have been derived from the synthetic gene. The amino acids from and including 23 to 101 have been marked off by square brackets. These are a repeat of i-Ag (see Clark et al., 1992, above). The glutamine codons TAA and TAG in the original sequence, which are the universal codons, are indicated by asterisks, and have been replaced with the universal glutamine codons CAG and CAA (underlined) in the synthetic gene. The restriction sites in the synthetic gene that are used for cloning have also been underlined. The changed nucleotides for the creation of the restriction enzyme sites, as well as for the replacement of the glutamine codons, have been shown in italics.

Referring now to Fig. 1(B), there is shown six (6) synthetic oligonucleotides that were used to construct the i-AgI epitope region. There are three (3) DNA segments, each of which is constructed with two (2) oligonucleotides that were derived from the coding strand (upper) and the non-coding strand (lower). The 3' complimentary nucleotides (12bp) have been aligned, and the 5' restriction sites and changed glutamine codons have been underlined.

Referring now to Fig. 1(c), there is shown a diagram of the plasmid pGST-iAgI used for the production of GST-iAgI protein. The 316 bp synthetic DNA fragment was inserted into pGEX2T vector between BamHI and EcoRI sites as described herein.

Referring now to Fig. 2(A), there are shown bacterial expressions of GST-iAgI fusion protein. Lanes 1-4 show total lysate of bacteria transformed with pGEX2T (lanes 1 and 2), or with pGST-iAgI (lanes 3 and 4). Lanes 1 and 3 had no IPTG induction, and lanes 2 and 4 had IPTG induction. Lane 5 shows purified GST-iAgI with thrombin digestion and lane 6 shows GST-iAgI without thrombin digestion. The GST-iAgI was cleaved into two (2) parts, as indicated. The SDS-PAGE was stained with coomassie brilliant blue. The position of the protein is indicated by the solid dot on the right of each lane. M was a prestained protein standard (Gibco, Life Sciences) in KDa.

Referring now to Fig. 2(B), which is a Western Blot analysis, in lane 1 there is shown GST-iAgI fusion protein that has been partially digested with thrombin. The solid dots indicate intact fusion protein GST and i-AgI. In lane 2 there is shown the Tomite total protein. M indicates a high range of prestained protein standard (Gibco, Life Sciences) in KDa.

## MATERIALS AND METHODS

### DESIGN, SYNTHESIS AND ASSEMBLY OF THE 'iAGI' GENE

The immobilization antigen of *I. Multifiliis* (i-AgI) consisted of three tandem repeats in its central region. Three DNA segments of similar length were designed to cover a complete repeat I of i-AgI. For each segment, two oligonucleotides, representing both coding and noncoding strands, were synthesized. To ensure efficient intermolecular annealing, the two oligonucleotides contained 12 complementary nucleotides at their 3' ends (Fig. 1B). Restriction sites were engineered at the 5' ends of each oligonucleotide to facilitate cloning. To generate double-stranded DNA from the oligonucleotides, 10 µl each of the corresponding two oligonucleotides were mixed, at the same concentration (1 µg/µl), with 5µl of 10 X Klenow buffer (500mM Tris, pH7.2, 100mM MgSO<sub>4</sub>, 1mM dithiothreitol) and 18µl distilled water. The reaction mixture was heated and maintained at 80°C for 5 min and then allowed to cool to 37°C, followed by addition of 5 µl of 2.5mM deoxyribonucleotides (dNTP) and 2 µl of Klenow fragment (Promega) to initiate DNA

synthesis at room temperature. After 40 minutes EDTA was added to a final concentration of 10 mM to stop the reaction, and this was followed by incubation at 75°C for 5 min to inactivate the Klenow enzyme. The double-stranded DNA segments were purified by phenol/chloroform extraction and ethanol precipitation, and dissolved in 50 µl of distilled water. To assemble the three segments into a longer DNA fragment, half of double-stranded segments 1, 2 and 3 were double digested with BamHI-KpnI, KpnI-Sau3A1 and Sau3A1-EcoRI, respectively. The digested segments were recovered by gel purification, using low-melting-temperature agarose, and dissolved in 25 µl of water. About 0.1 µg of digested segment 1 was ligated into 0.1 µg of pBluescript vector (Stratagene) that had been predigested with BamHI and KpnI. The ligation was performed overnight at 4°C in a 20 µl reaction mixture. Similarly, 0.2 µg each of segment 2 and segment 3 were ligated together into pBluescript vector (Stratagene) that had been predigested with KpnI and EcoRI. 10 µl of each ligation reaction mixture was transferred into 100 µl of *E. coli* competent cell (XL1-Blue strain, Stratagene) according to the standard protocol described by Sambrook, J., Fritsch E.F. and Maniatis, T. ("MOLECULAR CLONING, A LABORATORY MANUAL" 2<sup>nd</sup> edition, Cold Spring Harbor Laboratory Press, New York, 1989). The resulted plasmids were isolated with Qiagen Plasmid Isolation Kit (Qiagen) and sequenced from both ends for confirmation. The verified segment 1 and segments 2 and 3 were removed from pBluescript by digestion with BamHI-KpnI and KpnI-EcoRI respectively. 0.1 µg of verified segment 1 and segments 2 and 3 each were ligated into 0.1 µg of pGEX2T (Pharmacia) vector cut with BamHI and EcoRI. The volume of 10 µl ligation reaction was transformed into *E. coli* (XL1-Blue strain, Stratagene), and the resulting construct was called pGST-iAgI. Its sequence was confirmed again by sequencing with the primer 5'-TAGCATGGCCTTTGCAG-3', upstream of the cloning site of pGEX2T vector.

## EXPRESSION AND PURIFICATION OF GST FUSION PROTEIN

An overnight culture of *E. coli* harboring pGST-iAgI was diluted to 1:20 in fresh LB medium containing 50 µg/ml ampicillin and grown at 37°C with vigorous shaking. Isopropyl 1-thio-β-D-galactoside (IPTG) was added to a final concentration of 0.1 mM when the OD<sub>600</sub> reached about 0.5. Bacteria were harvested, by centrifugation at 2,000 G

at 4°C for 15 min, 3 hours after the addition of IPTG. The bacteria were resuspended in 300 µl of phosphate-buffered saline (PBS), boiled in SDS-sample buffer for 5 min and analyzed by electrophoresis (according to Laemmli, U.K., "CLEAVAGE OF STRUCTURE PROTEIN DURING THE ASSEMBLY OF THE HEAD OF BACTERIOPHAGE T4" *Nature*, 227(1970) 680-685)) using an SDS-polyacrylamide gel.

The GST-iAgI fusion protein was purified using Glutathione Sepharose 4B Beads (Pharmacia) as previously described (Gong, Z. and Hew, C.L., "ZINC AND DNA BINDING PROPERTIES OF A NOVEL LIM HOMEODOMAIN PROTEIN ISL-2", *Biochemistry*, 33 (1995)15149-15158). Shortly after IPTG induction, 1 liter of bacterial culture was harvested by centrifugation and resuspended in 10 ml of lysis buffer (50 mM Tris, pH8.0, 0.1M NaCl, 1mM EDTA), to which lysozyme had been added to a final concentration of 5 mg/ml. After incubation at room temperature for 5 min, bacteria, that were lysed with 1% Triton-100. MgCl<sub>2</sub> and DNase I, were then added, in amounts sufficient to produce final concentrations of 5mM and 10µg/ml respectively, to digest viscous DNA. The lysate was cleared by centrifugation. The supernatant was incubated with 1 ml of a 50% slurry of Glutathione Sepharose 4B Beads (Pharmacia) at room temperature for 1 hour with gentle agitation. The beads were then washed three times in 10X of bed volume of PBS. The GST-iAgI fusion protein was eluted from beads with 15 mM reduced glutathione (Sigma). The concentration of purified fusion protein was measured using Bio-Rad Protein Assay (Bio-Rad). Thrombin (Sigma) digestion of purified pGST-iAgI fusion protein was carried out according to the method described by Smith, D.B. and Johnson, K.S. "SINGLE-STEP PURIFICATION OF POLYPEPTIDES IN *ESCHERICHIA COLI* AS FUSION GLUTATHIONE S-TRANSFERASE" *Gene*, 67 (1988)31-40.

#### ANALYSIS OF ANTIGENICTY OF GST-iAGI FUSION PROTEIN BY WESTERN BLOT.

Catfish, of 20-25 cm in length, were immunized by intraperitoneal injection of 200 µg of GST-iAgI fusion protein mixed with Freund's complete adjuvant (FCA). A similar

dose of the fusion protein, without FCA, was repeated two weeks later. Pre-immunization sera were collected from each fish prior to immunization. Post immunization sera were collected one week after the second injection. Infectious tomites were collected according to the method as previously described (Ling, K.H, Sin, Y.M. and Lam, T.J., "PROTECTION OF GOLDFISH AGAINST SOME ECTOPARASITIC PROTOZOANS USING *ICHTHYOPHTHIRIUS MULTIFILIIS* AND *TETRAHYMENA PYRIFORMIS* FOR VACCINATION", Aquaculture, 116 (1993)303-314).

The tomites and thrombin digested GST-iAgI fusion protein were boiled in SDS sample buffer for 5 min, and analyzed by electrophoresis using an SDS-polyacrylamide gel. The resolved protein was electroblotted onto a 0.2  $\mu$ m nitrocellulose filter. For immunodetection, the filter was blocked in 0.5% bovine serum albumin (BSA) in TTBS (0.05% Tween- 20, 10 mM Tris-HCl, 150 mM NaCl, pH7.5) at 4°C for 16 hours, followed by incubating with 1:50 primary antibody (catfish antisera against GST-iAgI fusion protein) overnight at 4°C. After three washes with TTBS, the filter was incubated with 1:100 of rabbit anti-catfish serum for 1 hour and then with 1:3,000 dilution of goat anti-rabbit IgG alkaline phosphate conjugates for 1 hour (Bio-Rad). The filter was washed with TTBS and incubated with substrate NBT (nitroblue tetrazolium ) and BCIP(5-bromo-4-chloro-3-indoyl phosphate) for color development at room temperature.

#### CHALLENGE TEST WITH INFECTIOUS TOMITES

Goldfish, *Carassius auratus* (L.), weighing 5-6 gms, were used throughout the study. All fish were bred from healthy broodstock and were not previously infected by *I. Multifiliis* nor by any other obvious parasites. The fish were maintained in the laboratory as described previously (Ling, K.H., Sin, Y.M. and Lam, T.J., "A NEW APPROACH TO CONTROLLING ICHTHYOPHTHIRIASIS IN A CLOSED CULTURE SYSTEM OF FRESHWATER ORNAMENTAL FISH", J. Fish Dis., 14 (1991) 595-598).

Each fish was immunized by intraperitoneal injection of 15  $\mu$ g GST-iAgI fusion protein with FCS and boosted, by the injection of a similar dose of GST-iAgI fusion

protein without the adjuvant, two weeks later. The control group was similarly injected with PBS and FCA mixture at the first injection, and then boosted with PBS alone. One week after the last injection, the control and immunized fish were challenged by direct exposure to infectious tomites using the method of Ling, K.H., Sin, Y.M. and Lam, T.J., "A NEW APPROACH TO CONTROLLING ICHTHYOPHTHIRIASIS IN A CLOSED CULTURE SYSTEM OF FRESHWATER ORNAMENTAL FISH", J. Fish Dis., 14(1991) 595-598. Each fish of all groups was exposed to 5,000 tomites. The fish were kept in aerated water at room temperature for four weeks under observation for infection and death. The degree of infection was separated and recorded in three (3) categories: none (free of parasites), mild, and heavy infection. Fish infected with less than 100 parasites per fish, and had parasites only on their fins were considered to have a mild infection. Those infected with more than 100 parasites, and not only on their fins but also on their body surface, were considered to have a heavy infection. The significance of the survival rate of fish between the immune and the control group after challenge was analysed by Chi-square test.

## SPECIFIC EXAMPLES AND RESULTS

### Example 1.

The amino acid sequence of i-AgI (Clark, T.G., McGraw, R.A. and Dickerson, H.W., "DEVELOPMENTAL EXPRESSION OF SURFACE ANTIGEN GENES IN THE PARASITIC CILIATE *ICHTHYOPHTHIRIUS MULTIFILIIS*", Proc. Natl. Acad. Sci. USA, 89 (1992) 6363-6367) was analyzed by a computer program to determine if it had a potential antigenic epitope, Predict 7 V1.01© (Carmenes, R.S., Freije, J.P., Molina, M.M. and Martin, J.M., "PREDICT 7, A PROGRAM FOR PROTEIN STRUCTURE PREDICTION", Biochem. Biophys. Res. Commun., 159 (1989) 687-693). It was predicted that each of the three repeats could be a strong antigenic epitope. The repeat I (Fig.1A) was selected for expression of the recombinant protein for immunization.

Three pairs of oligonucleotides were designed and synthesized to cover the repeat I of i-AgI (see Fig. 1). For the expression of i-AgI recombinant protein, the assembled gene fragment was inserted into the bacterial expression vector pGEX2T and the resulting



plasmid was named pGST-iAgl (see Fig. 1). As shown in Fig.2(a), the expression of GST-iAgl fusion protein can be induced after addition of IPTG (lane 4 ). The GST-iAgl fusion protein can be purified by glutathione Sepharose 4B bead (lane 6), and the purified GST-iAgl fusion protein can be cleaved at the fusion site with thrombin (lane 5). The yield of GST-ich fusion protein, purified from 1liter bacterial culture, was 2.7-3.0 mg.

#### Example 2.

To test whether the recombinant protein contained the antigenic epitope for i-Agl, antisera against GST-iAgl fusion protein were raised in catfish and tested for immunological reaction with the total tomite's proteins. As shown in Fig. 2(b), the catfish antisera reacted strongly to the intact fusion protein, as well as to the GST and the iAgl portions after thrombin digestion (lane 1). It is interesting to note that the catfish antisera also reacted with a tomite's protein of a molecular weight of about 48K (lane 2). This is consistent with the predicted molecular weight of i-Agl. All the sera obtained from fish prior to immunization were negative (data not shown).

#### Example 3.

To test the effectiveness of the GST-iAgl as a vaccine, naive goldfish were immunized with the fusion protein and then challenged with infectious tomite of *I. Multifiliis*. Clinical signs of the disease and mortalities of the fish were recorded from day 4 onwards after the exposure to these tomite. The result are summarized in Table 1. 22.7% of the immunized fish showed no clinical sign of the disease, while 50% of the immunized fish exhibited heavy infection, and 27.3 % showed a mild infection. In contrast, all the control fish were infected: 75% of non-immunized fish were heavily infected, and the other 25% were mildly infected. The average survival rate of the immunized fish was 95% as compared to 55% for the control. The difference between the survival rate of the control and of the immunized group is significant,  $p < 0.001$  as determined by Chi-square-sequare test.

Table 1: Infectivity and average survival rate of control and immunized fish after being exposed to infective tomites of *I. Multifiliis*.

Group	Total fish *	Degree of infectivity (%)**			Survival (%)***
		heavy	mild	none	
Control	20	75	25	0	55%
Immune	22	50	27.2	22.8	95%

\*Two duplicate groups of 10 to 12 fish each.

\*\*Heavy : the number of parasites found on the fish body and fins was more than 100 up to 500-1,000; Mild: the number of parasites found only on the fins was less than 100; None: the fish were free of parasites.

\*\*\* significantly different at  $p < 0.001$  level, between control and immunized fish by the Chi-square test.

#### **FURTHER APPLICATION OF THE RECOMBINANT VACCINE**

The effectiveness of this recombinant vaccine in immune protection against *Ichthyophthirius multifiliis* has been demonstrated in fish (He, J., Yin, Z, Xu, G., Gong Z., Lam T.J. and Sin Y.M., "PROTECTION OF GOLDFISH AGAINST *ICHTHYOPHTHIRIUS MULTIFILIIS* BY IMMUNIZATION WITH A RECOMBINANT VACCINE", Aquaculture, 158 (1997)1-10). The antigenicity of the vaccine was also shown using antisera against GST fusion protein from catfish that reacted strongly to the protein of *I. Multifiliis* of a similar size (48 KDa) to that of the immobilization antigen of *I. Multifiliis* (i-AgI) as reported by Clark, T.G., McGraw, R.A. and Dickerson, H.W., "DEVELOPMENTAL EXPRESSION OF SURFACE ANTIGEN GENES IN THE PARASITIC CILIATE *ICHTHYOPHTHIRIUS MULTIFILIIS* ", Proc. Natl. Acad. Sci. USA, 89 (1992) 6363-6367). In fact, fish immunized with the immobilization protein of *I. Multifiliis* and *T. pyriformis* showed protection against the disease caused by *I. Multifiliis* in freshwater fish (Goven , B.A., Dawe, D.L. and Gratzek, J.B., "PROTECTION OF CHANNEL CATFISH, *ICTALURUS PUNCTATUS* RAFINESQUE, AGAINST *ICHTHYOPHTHIRIUS MULTIFILIIS* FOUQUET BY IMMUNIZATION", J. Fish Biol., 17 (1980) 311-316; Goven,B.A., Dawe, D.L and Gratzek, J.B., " *IN VITRO*

DEMONSTRATION OF SEROLOGICAL CROSS-REACTIVITY BETWEEN *ICHTHYOPHTHIRIUS MULTIFILIIS* FOUQUET AND *T. PYRIFORMIS* LWOFF", Dev. Comp. Immunol., 5 (1981) 283-289 ) and *Cryptocryon* in marine fish (U.S. Patent Number 4,309,416). The immune protection was correlated with the levels of immobilization antibody in the plasma and skin mucus of the freshwater fish immunized against *I. Multifiliis* or *T. pyriformis* (Clark , T.G., Dickerson, H.W., and Findly, R.C., "IMMUNE RESPONSE OF CHANNEL CATFISH TO CILIARY ANTIGENS OF *ICHTHYOPHTHIRIUS MULTIFILIIS*", Devel. Comp. Immunol., 12 (1988) 581-594; Ling, K.H., Sin, Y.M. and Lam T.J., "PROTECTION OF GOLDFISH AGAINST SOME COMMON ECTOPARASITIC PROTOZOANS USING *ICHTHYOPHTHIRIUS MULTIFILIIS* AND *TETRAHYMENA PYRIFORMIS* FOR VACCINATION", Aquaculture, 116 (1993) 303-314). An immobilization antigen extracted from *T. pyriformis* was also shown to be an effective vaccine against *I. Multifiliis* and *Cryptocryon* in marine fish (U.S. Patent Number 4,309,416). Since fish immunized with either *I. Multifiliis* or *T. pyriformis* developed protective immunity not only against *I. Multifiliis* but also against other ciliated ectoparasitic protozoans that are commonly found in the tropics, therefore, the recombinant vaccine made for the immobilization antigen of *I. Multifiliis* should also exert the same immune protection not only against *I. Multifiliis* but also against other taxonomically related ciliated ectoparasitic protozoans in the freshwater and the marine fish.

For immunization by injection, the fusion protein was dissolved in buffer and mixed with Freund's complete adjuvant (FCA). Any substance or medium that does not chemically destroy or interfere with the immunogenicity of the fusion protein can be incorporated into the formulation of the vaccine. These include, for example, buffers, immunostimulants and carriers. The vaccine can be introduced to fish by intraperitoneal injection, incorporated into fish diet, and by immersion or by spraying of the fish. For injection of a 5-6 gm fish, at least about 15 µg of the fusion protein is required. That is, a dose rate of at least about 3 µg fusion protein per gram of fish is appropriate.

## SEQ. ID NO 1

G A/S A Q\* G E A N G N Q\* P F A A N N A A R G I [ C V P C Q I N R V G S V / G T N A G  
D L A T L A T Q\* C S T Q\* C P T G T A L D D G V T D V F D R S A A Q\* C V K C K P N  
F Y Y N G G S P Q\* G E A P G V Q\* V F A A G A A ] A A G V / I \*

## SEQ. ID NO 2

GGT GCT GCT TAA GGA GAA GCT AAT GCT AAT TAA CCT TTC GCA GCA AAT AAT GCT  
GCT AGA GGT ATA TGT GTA CCA TGC CAA ATA AAC AGA GTA GGC TCT GTT ACC AAT  
GCA GGT GAC TTA GCT ACT TTA GCC ACA TAA TGC AGT ACT TAA TGT CCT ACT GGC  
ACT GCA CTT GAT GAT GGA GTG ACA GAT GTT TTT GAT AGA TCA GCC GCA TAA TGT  
GTT AAA TGC AAA CCT AAC TTT TAC TAT AAT GGT GGT TCT CCT TAA GGT GAA GCT  
CCT GGC GTT TAA GTT TTT GCT GCT GGT GCT GCC GCT GCA GGT GTT G

## SEQ. ID NO 3

GGA TCC GCT CAG GGA GAA GCT AAT GGT AAT CAG CCT TTC GCA GCA AAT AAT GCT  
GCT AGA GGT ATA TGT GTA CCA TGC CAA ATA AAC AGA GTA GGC TCT CGT ACC AAT  
GCA GGT GAC TTA GCT ACT TTA GCC ACA CAA TGC AGT ACT CAG TGT CCT ACT GGC  
ACT GCA CTT GAT GAT GGA GTG ACA GAT GTT TTT GAT AGA TCA GCC GCA CAG TGT  
GTT AAA TGC AAA CCT AAC TTT TAC TAT AAT GGT GGT TCT CCT CAG GGT GAA GCT  
CCT GGC GTT CAG GTT TTT GCT GCT GGT GCT GCC GCT GCA CGA ATT C

**CLAIMS**

1. A vaccine for immunizing fish against ciliated ectoparasitic protozoans comprising an effective amount of a recombinant fusion protein derived from an artificial DNA sequence for immobilization antigen, repeat I, of *Ichthyophthirius multifiliis*.
2. The vaccine according to claim 1 wherein the fusion protein is GST-iAgI.
3. The vaccine according to claim 1 further comprising a substantially inert medium comprising at least one of buffers, adjuvants, immunostimulants or carriers.
4. The vaccine according to claim 1 having the property that, when it is injected into a fish, provides effective protection against white spot disease caused by *Ichthyophthirius multifiliis*.
5. The vaccine according to claim 2, wherein the fusion protein is produced using E-coli.
6. The vaccine according to claim 4, wherein disease is caused by at least one ciliated ectoparasitic protozoan.
7. The vaccine according to claim 6 wherein said ciliated protozoan consists of *Ichthyophthirius multifiliis*.
8. The vaccine according to claim 1 wherein said ciliated protozoans are taxonomically related to *Ichthyophthirius multifiliis*.
9. A method of immunizing fish against ciliated ectoparasitic protozoans comprising treating said fish with an effective amount of a vaccine according to claim 1.
10. The method as claimed in claim 9 wherein said fish are intraperitoneally injected with said vaccine.

11. The method as claimed in claim 9 wherein said fish are fed a medium comprising said vaccine.

12. The method as claimed in claim 9 wherein said fish are dipped in a medium comprising said vaccine.

13. The method as claimed in claim 9 wherein said fish are sprayed with a medium comprising said vaccine.

14. A method of producing a recombinant vaccine against ciliated ectoparasitic protozoans comprising:

- a. selecting a region of a amino acid sequence containing a single repeat of *Ichthyophthirius multifiliis* immobilization antigen epitope (i- Ag I);
- b. constructing a gene for the selected region from a plurality of synthetic oligonucleotides based on said i-AgI amino acid sequence using universal codons in place of ciliate codons to produce an i-AgI epitope;
- c. expressing said i-AgI epitope as a glutathione S transferase (GST) fusion protein in bacteria, *E. coli*; and
- d. purifying said GSH-iAgI fusion protein using a glutathione sepharose.

15. The method according to claim 14 wherein said ciliated ectoparasitic protozoans are taxonomically related to *Ichthyophthirius multifiliis*.

16. The method according to claim 14 wherein said ciliated ectoparasitic protozoans comprise *Ichthyophthirius multifiliis*.

17. A method of immunizing fish against ciliated ectoparasitic protozoans comprising treating said fish with an effective amount of a vaccine made according to claim 14.

18. The method as claimed in claim 17 wherein said fish are intraperitoneally injected with said vaccine.

19. The method as claimed in claim 17 wherein said fish are fed a medium comprising said vaccine.

20. The method as claimed in claim 17 wherein said fish are dipped in a medium comprising said vaccine.

21. The method as claimed in claim 7 wherein said fish are sprayed with a medium comprising said vaccine.

22. A synthetic nucleic acid sequence corresponding to SEQ ID No. 3.

23. A synthetic amino acid sequence corresponding to SEQ ID NO. 1

ABSTRACT OF THE DISCLOSURE

**A RECOMBINANT VACCINE AGAINST INFECTIOUS DISEASE IN FISH**

A recombinant vaccine that is useful for immunizing fish against ciliated ectoparasitic protozoans that cause white spot disease also known as 'ich'. The disease is caused by *Ichthyophthirius multifiliis* which is a ciliated ectoparasitic protozoan that is an obligate parasite and therefore cannot grow *in vitro*. The instant vaccine replaces chemotherapy and vaccines prepared from *I. Multifiliis* production in live fish. The effective element of the vaccine is a recombinant fusion protein derived from an artificial DNA sequence for immobilization antigen, repeat I, of *Ichthyophthirius multifiliis*. The novel DNA nucleotide and amino acid sequences are disclosed.

(Fig. 2(A) is to be published.)



A:

I 1 G A/S A Q\* G E A N G N Q\* P F A A N N A 18  
 II 5' 110 GGT GCT GCT TAA GGA GAA GCT AAT GGT AAT TAA CCT TTC GCA GCA AAT AAT GCT 164  
 III 5' 1 GGATCCGCT AAAGGA GAA GCT AAT GGT AAT AAAGCCT TTC GCA GCA AAT AAT GCT 54  
 BamHI

A R G I [C V P C Q I N R V G S V/G T N 35  
 GCT AGA GGT ATA TGT GTA CCA TGC CAA ATA AAC AGA GTA GGC TCT GTT ACC AAT 218  
 GCT AGA GGT ATA TGT GTA CCA TGC CAA ATA AAC AGA GTA GGC TCT GAAGCC AAT 108  
 KpnI

A G D L A T L A T Q\* C S T Q\* C P T G 54  
 GCA GGT GAC TTA GCT ACT TTA GCC ACA TAA TGC AGT ACT TAA TGT CCT ACT GGC 272  
 GCA GGT GAC TTA GCT ACT TTA GCC ACA AAA TGC AGT ACT AAAGTGT CCT ACT GGC 162

T A L D D G V T D V F D R S A A Q\* C 72  
 ACT GCA CTT GAT GAT GGA GTG ACA GAT GTT TTT TTT GAT AGA TCA GCC GCA TAA TGT 326  
 ACT GCA CTT GAT GAT GGA GTG ACA GAT GTT TTT GAT AGA ICAGCC GCA AAAGTGT 216  
 Sau3AI

V K C K P N F Y Y N G S P Q\* G E A 90  
 GTT AAA TGC AAA CCT AAC TTT TAC TAT AAT GGT GGT TCT CCT TAA GGT GAA GCT 380  
 GTT AAA TGC AAA CCT AAC TTT TAC TAT AAT GGT GGT TCT CCT AAAGGT GAA GCT 270

P G V Q\* V F A A G A A G V/I\* 105  
 CCT GGC GTT TAA GTT TTT GCT GCT GGT GGT GCT GGT GGT GGT GGT G 426 3'  
 CCT GGC GTT AAAGTGT TTT GCT GCT GCT GCT GCT GCT GCA GAATTC 316 3'  
 EcoRI

B:

Segment 1:  
 5' ggcggatccgctcaggagagagctaatggtaatcagccttttcgcagcaataatgctgtagagg 3'  
 3' ttacgacgatctccatatcacacatggtacgggtttatttctctatccgagaccatggcca 5'  
 BamHI KpnI

Segment 2:  
 5' accggatcccaatgcagggtgacttagctactttaggcacacaaatgcagtagctcagtgctcactggc 3'  
 3' gtacaggatgacccgtgacgtgaaactactacctcactggtctacaaaaaactatcttagtgc 5'  
 KpnI Sau3AI

Segment 3:  
 5' cctgatcagccgcacagtggtttaaatgcaaaacctaaacttttactataatgggtggttctcctcagggt 3'  
 3' ccaaggagggtcccactttcgaggaccgcaagtcacaaaacgacgaccacggcgacggtcctttaaaggc 5'  
 Sau3AI EcoRI

C:




Fig. 1. A: The epitope of i-Ag included in the GST-iAgl recombinant protein. The amino acid sequence (I) and corresponding nucleotide sequences from the original i-Ag cDNA clone (II) and the synthetic DNA fragment (III) are aligned. Two conserved amino acid substitutions between the original and synthetic i-Agl DNAs are indicated as A/S and V/G, where S and G are derived from the synthetic gene. The amino acids 23-101 in the square bracket are repeat I of i-Ag (Clark et al., 1992). The glutamine codons TAA and TAG in the original sequence, which are universal termination codons, are indicated by asterisks, and replaced with the universal glutamine codon CAG or CAA (underlined) in the synthetic gene. The restriction sites in the synthetic gene used for cloning are also underlined. The changed nucleotides for the creation of restriction enzyme sites, as well as for the replacement of the glutamine codons, are shown in italics. B: Six synthetic oligonucleotides used to construct the i-Agl epitope region. There are three DNA segments, each of which is constructed with two oligonucleotides derived from the coding strand (upper) and the noncoding strand (lower). The 3' complementary nucleotides (12 bp) are aligned, and the 5' restriction sites and changed glutamine codons are underlined. C: Diagram of the plasmid pGST-iAgl for production of GST-iAgl protein. The 316 bp synthetic DNA fragment was inserted into pGEX2T vector between the BamHI and EcoRI sites as described in Section 2. GST, glutathione S-transferase; AmpR, ampicillin resistant gene; Ori, replication origin; i-Agl, synthetic repeat I of i-Ag peptide; lac Iq, lac repressor.




Fig. 2. A: Bacterial expression of GST-iAgl fusion protein. Lanes 1–4, total lysate of bacteria transformed with pGEX2T (lanes 1–2), or with pGST-iAgl (lanes 3–4). Lanes 1 and 3, without IPTG induction, lanes 2 and 4 with IPTG induction. Lanes 5–6, purified GST-iAgl with (lane 5) or without (lane 6) thrombin digestion. GST-iAgl was cleaved into two parts as indicated by the asterisk. The SDS-PAGE gel was stained with coomassie brilliant blue. The position of protein is indicated in asterisk on the right of each lane. M: prestained protein standard (Gibco, Life Science) in KDa. B: Western Blot analysis. Lane 1: GST-iAgl fusion protein partially digested with Thrombin, as pointed by asterisks from top to bottom: intact fusion protein, GST and i-Agl; Lane 2: Tomite total protein. M: High range of prestained protein Standard (Gibco, Life Sciences) in KDa.